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Summary: Mediterranean Journal of Hematology and Infectious Diseases (MJHID) is a new 
open access, peer-reviewed, online journal, which encompasses different aspects of clinical 
and  translational  research  providing  an  insight  into  the  relationship  between  acute  and 
chronic infections and hematological diseases. MJHID will be a topical journal on subjects of 
current importance in clinical haematology and infectious diseases. Every issue should have, 
beside the editor in chief, a guest editor. Both editor in chief and guest editor provide to invite 
experts in the selected topic to performe a complete update of the arguments readily available 
for practising phisicians. The journal will have also a section devoted to original papers, case 
reports and letters to editor and Editorial comment mostly focusing on the arguments treated 
in the previous topical issues.
Reciprocal interdependence between infectious 
and  haematologic  diseases  (malignant  and  non 
malignant)  is  well  known.
1,2,3,4 Parassitosis  as 
Malaria,  Leishmaniosis,  Hookworms  and  Teniasis 
infect  about  a  billion  people  in  the  word
5,6 and 
anifest prevalently with anaemia,
7,8 so that they are 
diagnosed  mostly  by  experienced  haemato-logists
on blood or bone marrow smear.
9 Malaria has been 
of  prominent  importance  in  the  diffusion  of 
thalassemia and related disorders in Mediter-ranean 
countries and in the rest of the world.
10On the other 
hand,  infections  are  also  the  main  problem  in 
patients affected by hematological malignancies.
11-
15 Granulocytopenia,  due  to  bone  marrow 
infiltration  or  to  radio-chemotherapy  is  the  main 
factor favouring bacterial and fungal infections
16-18
and  immunodeficiency,  frequent  in  lympho-
proliferative  diseases,  favours  viral,  protozoal  as 
well as fungal infections.
19-22 Furthermore, most of
the drug utilized to eradicate malignant clones 
23-24
have as a side effect immunosuppression, which, on 
the  other  hand,  is  requested  to  reduce 
immunological  competence  in  autoimmune  blood 
diseases  and  to  reduce  GVH  and  rejection  in 
Hemopoietic Stem Cell Transplantation.
25-27
Splenectomy frequently performed autoimmune 
diseases as well in lymphoproliferative diseases is a 
further cause of immunodeficiency.
28
Nevertheless,  the  main  cause  of 
immunodeficiency  at  present  is  due  to  HIV 
infection  in  developed  as  well  in  developing 
countries.
29 The blood  is  the  main  vector  of  HIV 
infection,  which  become  manifest  with  symptoms 
related to  reduction  of  T  lymphocytes 
30-35 and 
consequent bacterial, viral and fungal and protozoan 
infections.
36-38 In  turn,  infections  and 
immunosupression favours malignancies especially 
of lymphoid tissue in HIV patients
39-45 and, even if Medit J Hemat Infect Dis 2009; 1(1); Open Journal System
in a lower proportion in non HIV.
1Worldwide 15 to 
20% of cancers are linked to infectious diseases.
1 In 
developed  Western  Countries  approximately  10% 
of  all cancers  are linked  to infectious  agents,  but 
they account for as much as 20% of all cancers in 
developing countries.
1 It is noteworthy that the first 
infection driven neoplasia, the bladder cancer, was 
recognized  in  egyptian  farmers  affected  by 
schistosomiasis.
45 Most of malignancies associated 
with  infections  and/or  immunosuppression  are 
hematological.
1 Causative  relationship  between 
Epstein-Barr virus infection, virus C hepatitis, HIV, 
Herpes Virus,
8 helicobacter pylori and B lympho-
proliferative  diseases  are  well  known
47-51
furthermore  association  between  human  T-
lymphotropic  viruses  and  adult  T-cell  leukemias 
and lymphomas are frequent in in endemic areas.
52-
53 Endemic chronic infections are more frequent in 
developing countries and probably justify the major 
frequency of  cancers linked to infections in these 
countries.
1 Although the european and afro-middle 
oriental mediterranean countries are heterogeneous
in life style, income, average life and public health 
system, and include both developed and developing
countries they share epidemiological characteristics 
and  public  health  problems.
60 It  is  evident  the 
interest  of  Mediterranean  European  countries  to 
increase the research in  the infectious diseases  of 
Mediterranean  basin  not  only  for  humanitarian 
reasons  but  also  for  their  specific  interests.
60
Pathogens  can  spread  far  from  where  they  first 
developed  due  to  increases  in  trade,  international 
tourism  and  climate  change.
60-64 It  is  noteworthy 
that  the  infections  in  developing  countries  are 
considered  a  priority  in  the  research  program  of 
European  Community.
60 Neglected  diseases  are  a 
major  problem  of  present  medicine  . It  is  now 
commonly  admitted  that  the  so-called  (most) 
neglected  tropical  diseases  have  been  given  little 
attention. According to World Health Organization, 
neglected  diseases  are  hidden  diseases.
4-5 On  a 
global scale, neglected infectious diseases (NID) are 
responsible  for  an  estimated  500 000  deaths  and 
millions  of  disabilities  each  year. They  affect 
almost  exclusively  extremely  poor populations 
living in remote areas beyond the reach of health 
service. Moreover, due to the fact that 90% of cases 
occur  in  the  low  income countries,  investment  in 
research  on  these  diseases  has  been  utterly 
inadequate.
5 Investing  for  discover  new  drugs  for 
these diseases is  thought to  be not  marketable  or 
profitable.  However,  there  is  an  increasing 
awareness of this gap, which has been highlighted 
in a recent report on major and neglected diseases in 
developing countries prepared by MEP John Bowis 
and adopted by the European Parliament in 2005.
65
Urgent  pragmatic  and  efficient  measures  are 
needed  both  at  international  and  national  levels. 
Most of the peoples affected by neglected infectious 
diseases live in Central Africa, South Asia 
5 and , 
however  Mediterranean  basin  represent  from 
epidemiological  point  of  view  an  exclusive  cross 
road  of  Asian,  African  and  European  infectious 
diseases .
60Most of neglected infectious diseases are 
present in Mediterranean basin and their eradication 
in this area could represent a tremendous incentive 
to reduce their presence in the rest of the word. 
This  should  be  possible  bridging  the  health 
system gap between the south and the north borders 
sides  of  Mediterranean  Sea  while  improving 
scientific collaboration.
Case report should have educational character. 
Clinical  trials  of  hematologic  and  infectious 
diseases  present  of  Mediterranean  area  will  have 
their natural home in this Journal. Also case studies 
relative  to  important  health  care  intervention  in 
developing countries of south Mediterranean areas 
will  be  accepted.  All  that  should  contribute  to 
disseminate updated informations among physicians 
of  developing  countries  on  the  more  frequent 
diseases of the Mediterranean area.
The  results  of  relevant  studies  in  the  field 
should  be  made  available  to  scientists  and 
clinicians,  in  particular  those  in  developing 
countries where the fight against pathogen related 
cancers is of the utmost importance. 
Every accepted manuscript will be available for 
reading on its date of acceptance by any person who 
has  access  to  the  web  in  web-friendly  XML. 
Considering that every issue will be devoted to a 
topic,  when all articles  of  the same  topic  will  be 
available  they  will  be  formatted  and  the  typeset 
PDF version will be available. The first issue of the 
MJHID has been dedicated to “Update in Diagnosis 
and  Treatment  of  Thalassemia  and  related 
Disorders”  Guest  Editor Prof.  Maria  Domenica 
Cappellini.
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